A Prospective, Open Label Study of CERtican in KIdney Transplantation
NCT01594268 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54
Last updated 2017-03-21
Summary
A prospective, open label study of CERtican in KIdney transplantation
Conditions
- Kidney Transplant
Interventions
- DRUG
-
A prospective, open-label study to assess safety of Certican in kidney transplant patients
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-03-31
- Primary Completion
- 2013-10-31
- Completion
- 2013-10-31
Countries
- South Korea
Study Locations
More Related Trials
-
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
NCT00634920 ·Status: COMPLETED ·Phase: PHASE4
-
Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors
NCT01653041 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Certican® in Combination With Myfortic® in Renal
NCT01399242 ·Status: UNKNOWN ·Phase: PHASE4
-
Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion
NCT00443508 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
NCT00504543 ·Status: COMPLETED ·Phase: PHASE2
-
Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation
NCT00377962 ·Status: COMPLETED ·Phase: PHASE4
-
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
NCT00154284 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
NCT00170820 ·Status: COMPLETED ·Phase: PHASE4
-
Safety & Efficacy of Certican in Pediatric de Novo Renal Transplant Patients
NCT00098241 ·Status: COMPLETED ·Phase: PHASE3
-
Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients
NCT00464399 ·Status: COMPLETED ·Phase: PHASE3
-
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
NCT06942156 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
NCT01028092 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study of Everolimus on Renal Function in Heart Transplant Recipients With Established Chronic Renal Failure
NCT00716573 ·Status: COMPLETED ·Phase: PHASE4
-
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
NCT00170794 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients
NCT00965094 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients
NCT01114529 ·Status: COMPLETED ·Phase: PHASE3
-
Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients
NCT01079143 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
NCT00862979 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults
NCT01455649 ·Status: UNKNOWN ·Phase: PHASE4
-
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
NCT00170885 ·Status: COMPLETED ·Phase: PHASE4
-
Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation
NCT00402532 ·Status: COMPLETED ·Phase: PHASE3
-
Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen
NCT00514514 ·Status: COMPLETED ·Phase: PHASE3
-
Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)
NCT01950819 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
NCT03663335 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Transplantation in the Elderly - nEverOld Study
NCT01631058 ·Status: UNKNOWN ·Phase: PHASE4